科研动态PubMed 摘要

婴幼儿、儿童和年轻成人肺动脉高压的治疗。欧洲儿科肺血管疾病网络(EPPVDN)2026年共识声明,获AHA、AEPC、EACTS、ESPR、PASCAR、PCS和PICS认可。

PubMed 白名单日捞 · 2026-11-03

完整摘要 · 中文译文

欧洲儿科肺血管疾病网络(EPPVDN)是一个注册的非营利组织,致力于推进所有形式儿科肺血管疾病的创新诊断方法和治疗方案,包括与先天性心脏病(CHD)相关的肺动脉高压(PH)、与发育性肺疾病相关的PH(DEVLD-PH)、新生儿持续性肺动脉高压(PPHN)、左心疾病中的毛细血管后PH(PH-LHD)以及相关的心脏功能障碍/心力衰竭。过去,EPPVDN已发布了关于儿科PH诊断和治疗的共识声明(2016年、2019年),并获得了多个学会的认可。执行写作组对PubMed/MEDLINE文献数据库(2000年至2025年)进行了全面检索,并参与了多次网络和面对面会议。十三个章节工作组进行了讨论并制定了经同意的建议。检索纳入了前瞻性临床研究、临床试验、荟萃分析、专家共识指南以及其他包含儿科数据的文章,使用的检索词为“肺动脉高压”及相关关键词。推荐等级(COR)和证据水平(LOE)依据AHA/ESC定义、儿科PH研究、包含最少15名儿童受试者的成人研究或涉及成人CHD的研究进行评定。纳入并讨论了2024年第七届世界肺动脉高压研讨会(WSPH)的分类和定义。我们制定了6个分级推荐表(COR、LOE)和3个算法用于tr 婴儿、儿童和年轻成人肺动脉高压的治疗。共16个主要和17个补充展示项目,涵盖一系列主题,包括风险评估、药物治疗、经导管介入和手术、针对肺动脉高压亚组/特殊人群和临床环境的特定建议。提供了中低收入地区管理建议的改编版本。总之,这些最新指南为婴儿、儿童和年轻成人肺动脉高压的治疗提供了全面、详细和实用的框架,旨在改善受影响患者的结局和生活质量。

完整摘要 · 英文原文

The European Pediatric Pulmonary Vascular Disease Network (EPPVDN) is a registered, non-profit organization dedicated to advancing innovative diagnostic methods and treatment options for all forms of pediatric pulmonary vascular disease, including pulmonary hypertension (PH) related to congenital heart disease (CHD), PH associated with developmental lung disease (DEVLD-PH), persistent PH of the newborn (PPHN), postcapillary PH in left heart disease (PH-LHD), and associated cardiac dysfunction/heart failure. In the past, the EPPVDN has published consensus statements on the diagnosis and treatment of pediatric PH (2016, 2019), which have been endorsed by multiple societies. The executive writing group conducted comprehensive searches of the PubMed/MEDLINE bibliographic database (2000 to 2025) and engaged in multiple web-based and in-person meetings. Thirteen section task forces discussed and created consented recommendations. Prospective clinical studies, clinical trials, meta-analyses, expert consensus guidelines, and other articles with pediatric data were included in the search, using the terms 'pulmonary hypertension' and related keywords. Classes of recommendation (COR) and levels of evidence (LOE) were assigned based on AHA/ESC definitions, pediatric PH studies, adult studies including a minimum N number of 15 children, or studies involving adults with CHD. Classifications and definitions from the 7th World Symposium on Pulmonary Hypertension (WSPH) in 2024 were incorporated and discussed. We produced 6 graded recommendation tables (COR, LOE) and 3 algorithms for the treatment of pulmonary hypertension in infants, children, and young adults. A total of 16 main and 17 supplemental display items cover a range of topics, including risk assessment, pharmacological therapy, transcatheter interventions and surgery, recommendations specific to PH subgroups/special populations and clinical settings. Adaptation of management recommendations for middle-to-low-income regions is provided. Together, these up-to-date guidelines provide a comprehensive, detailed, and practical framework for the treatment of pulmonary hypertension in infants, children and young adults, aiming to improve outcomes and quality of life for affected patients.

English
Treatment of pulmonary hypertension in infants, children and young adults. 2026 consensus statement from the European Pediatric Pulmonary Vascular Disease Network (EPPVDN), endorsed by AHA, AEPC, EACTS, ESPR, PASCAR, PCS, and PICS.
内容仅供参考,不构成诊疗建议,不能替代执业医师的诊断。

← 返回元界